Trial Profile

A Phase 2/3 pivotal confirmatory clinical trial for OCU410ST

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 07 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OCU 410 ST (Primary)
Indications Stargardt disease
Focus Registrational; Therapeutic Use
Acronyms GARDian3
Sponsors Ocugen

Most Recent Events

18 Jul 2025 Status changed from planning to recruiting.
18 Jul 2025 According to Ocugen media release, Victor H. Gonzalez, MD, Principal Investigator of the trial.
18 Jul 2025 According to Ocugen media release, company announced that the first patient has been dosed in this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com